Recent News

• 05.12.2026 - Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
• 05.12.2026 - Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
• 04.07.2026 - Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
• 04.07.2026 - Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
• 04.03.2026 - Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.03.2026 - Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.03.2026 - Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.26.2026 - Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
• 03.26.2026 - Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
• 03.26.2026 - Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Recent Filings

• 04.30.2026 - DEF 14A Other definitive proxy statements
• 04.30.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.30.2026 - ARS Annual Report to Security Holders
• 04.20.2026 - PRE 14A Other preliminary proxy statements
• 04.07.2026 - 8-K Current report
• 04.07.2026 - EX-99.1 EX-99.1
• 03.26.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.26.2026 - EX-99.1 EX-99.1
• 03.26.2026 - 8-K Current report
• 03.26.2026 - S-8 Securities to be offered to employees in employee benefit plans